Skip to main content

Articles

Page 11 of 13

  1. Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line...

    Authors: Patrizia Mondello, Vincenzo Pitini, Valeria Barresi, Elliott Joseph Brea, Cristian Di Mirto, Carmela Arrigo, Salvatore Cuzzocrea and Michael Mian
    Citation: Experimental Hematology & Oncology 2016 5:1
    Content type: Case report Published on:

  2. The programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 normally expressed by infiltrating immune cells in response to viral infection. The PD-1/PD-L1 ax...

    Authors: Diwakar Davar, Mark A. Socinski, Sanja Dacic and Timothy F. Burns
    Citation: Experimental Hematology & Oncology 2015 4:34
    Content type: Case report Published on:

  3. Hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2−) is the most common type of metastatic breast cancer (mBC). While mBC patients generally have poor prognosis with limited...

    Authors: Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo and Eric Q. Wu
    Citation: Experimental Hematology & Oncology 2015 4:31
    Content type: Research Published on:

  4. Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10–16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging technique...

    Authors: José Pablo Leone and Bernardo Amadeo Leone
    Citation: Experimental Hematology & Oncology 2015 4:33
    Content type: Review Published on:

  5. The clinical trials using immunotherapy have been performed for the treatment of variety of malignant tumors. However, large-scale meta-analysis of combined DC-CTL/CIK therapy on immune and clinical response i...

    Authors: Ying Wang, Zenghui Xu, Fuping Zhou, Yan Sun, Jingbo Chen, Linfang Li, Huajun Jin and Qijun Qian
    Citation: Experimental Hematology & Oncology 2015 4:32
    Content type: Research Published on:

  6. Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients’ tumors. These testing results have the potential to affect clinical care by g...

    Authors: Diana Mandelker, Paola Dal Cin, Heather A. Jacene, Philippe Armand, Richard M. Stone and Neal I. Lindeman
    Citation: Experimental Hematology & Oncology 2015 4:30
    Content type: Case report Published on:

  7. We conducted a retrospective review of the dose, toxicity, and efficacy of second line gemcitabine plus nab-paclitaxel (G + Nab-P) after FOLFIRINOX in patients with metastatic and locally advanced unresectable...

    Authors: Yue Zhang, Howard Hochster, Stacey Stein and Jill Lacy
    Citation: Experimental Hematology & Oncology 2015 4:29
    Content type: Research Published on:

  9. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is characterized by lymphocyte-predominant (LP) cells in a background of CD4+ CD57+ T-cells. These cells are normally present in the germinal center of l...

    Authors: Ahmad Sattarzadeh, Arjan Diepstra, Bea Rutgers, Anke van den Berg and Lydia Visser
    Citation: Experimental Hematology & Oncology 2015 4:27
    Content type: Short report Published on:

  10. Anemia is considered a negative prognostic risk factor for survival in patients with myelofibrosis. Most patients with myelofibrosis are anemic, and 35–54 % present with anemia at diagnosis. Ruxolitinib, a pot...

    Authors: Mary Frances McMullin, Claire N. Harrison, Dietger Niederwieser, Hilde Demuynck, Nadja Jäkel, Prashanth Gopalakrishna, Mari McQuitty, Viktoriya Stalbovskaya, Christian Recher, Koen Theunissen, Heinz Gisslinger, Jean-Jacques Kiladjian and Haifa-Kathrin Al-Ali
    Citation: Experimental Hematology & Oncology 2015 4:26
    Content type: Research Published on:

  11. Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleed...

    Authors: Arundhati Das and Delong Liu
    Citation: Experimental Hematology & Oncology 2015 4:25
    Content type: Review Published on:

  12. Therapeutic implications of intra-tumor heterogeneity are still undefined. In this study we report a genetic and functional analysis aimed at defining the mechanisms of chemoresistance in a 43-year old woman a...

    Authors: Enrico Derenzini, Ilaria Iacobucci, Claudio Agostinelli, Enrica Imbrogno, Clelia Tiziana Storlazzi, Alberto L`Abbate, Beatrice Casadei, Anna Ferrari, Andrea Ghelli Luserna Di Rora`, Giovanni Martinelli, Stefano Pileri and Pier Luigi Zinzani
    Citation: Experimental Hematology & Oncology 2015 4:24
    Content type: Case report Published on:

  13. IKZF1 deletions are an unfavorable prognostic factor in children with Philadelphia chromosome positive (Ph+) as well as negative (Ph−) acute lymphoblastic leukemia (ALL). Although IKZF...

    Authors: Naomi E van der Sligte, Frank J G Scherpen, Arja ter Elst, Victor Guryev, Frank N van Leeuwen and Eveline S J M de Bont
    Citation: Experimental Hematology & Oncology 2015 4:23
    Content type: Research Published on:

  14. In acute myeloid leukemia (AML), disseminated intravascular coagulation (DIC) contributes to morbidity and mortality, but the underlying pathomechanisms remain incompletely understood.

    Authors: Christina Dicke, Ali Amirkhosravi, Brigitte Spath, Miguel Jiménez-Alcázar, Tobias Fuchs, Monica Davila, John L Francis, Carsten Bokemeyer and Florian Langer
    Citation: Experimental Hematology & Oncology 2015 4:22
    Content type: Research Published on:

  15. Multiple myeloma (MM) is a clonal B cell malignancy characterized by proliferation of malignant plasma cells in the bone marrow. Despite high-dose melphalan therapy with autologous stem cell transplantation (A...

    Authors: Ruth-Miriam Koerber, Stefanie Andrea Erika Held, Annkristin Heine, Philipp Kotthoff, Solveig Nora Daecke, Anita Bringmann and Peter Brossart
    Citation: Experimental Hematology & Oncology 2015 4:21
    Content type: Research Published on:

  16. The outcomes of adult acute lymphoblastic leukemia (ALL) patients with chemotherapy or autologous hematopoietic stem cell transplantation (HSCT) are unsatisfactory. Therefore, allogeneic (allo) HSCT has been a...

    Authors: Masahiro Imamura and Akio Shigematsu
    Citation: Experimental Hematology & Oncology 2015 4:20
    Content type: Review Published on:

  17. The effect of sickle cell disease (SCD) on tumor growth is unknown. Sickled red blood cells may form aggregates within the microvasculature of hypoxic tumors and reduce blood flow leading to impairment of tumo...

    Authors: Jintao Wang, Jennifer Tran, Hui Wang, Wei Luo, Chiao Guo, David Harro, Andrew D. Campbell and Daniel T. Eitzman
    Citation: Experimental Hematology & Oncology 2015 4:19
    Content type: Research Published on:

  18. Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan...

    Authors: Magalie P. Tardy, Lauris Gastaud, Mario Ojeda-Uribe, Annick Boscagli, Salvatore Caruso, Richard Skaf, Jean Gutnecht, Antoine Thyss and Frédéric Peyrade
    Citation: Experimental Hematology & Oncology 2015 4:18
    Content type: Short report Published on:

  19. In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with 90Yttrium- ibritumomab tiuxetan (90Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were treated in ...

    Authors: Francesco Pisani, Rosa Sciuto, Maria Laura Dessanti, Diana Giannarelli, Ramy Kayal, Sandra Rea, Francesco Marchesi and Mirella Marino
    Citation: Experimental Hematology & Oncology 2015 4:17
    Content type: Research Published on:

  20. In view of the fact that certain non small cell lung carcinoma associated epidermal growth factor receptor mutations keep the receptor constitutively active, the downstream effectors of altered activity of mut...

    Authors: Arpana Kamath, Ann M Joseph, Kumud Gupta, Digamber Behera, Anand Jaiswal, Ravindra Dewan and Maitreyi S Rajala
    Citation: Experimental Hematology & Oncology 2015 4:16
    Content type: Letter to the Editor Published on:

  21. Hematological cancer survivors are growing in number and increasingly rely on oral therapy. Given known poor outcomes associated with non-adherence and previous evidence that many patients do not fully adhere ...

    Authors: Marita C. Lynagh, Tara Clinton-McHarg, Alix Hall, Rob Sanson-Fisher, William Stevenson, Campbell Tiley and Alessandra Bisquera
    Citation: Experimental Hematology & Oncology 2015 4:15
    Content type: Research Published on:

  22. Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm classified in the myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category. Molecular abnormalities are reported in about 90 % of pat...

    Authors: Yajuan Cui, Hongyan Tong, Xin Du, Bing Li, Robert Peter Gale, Tiejun Qin, Jinqin Liu, Zefeng Xu, Yue Zhang, Gang Huang, Jie Jin, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Shiqiang Qu…
    Citation: Experimental Hematology & Oncology 2015 4:14
    Content type: Research Published on:

  23. Mesenchymal stromal cells (MSCs) are proven to have immunosuppressive functions via various mechanisms. These mechanisms were demonstrated by administering bone marrow derived human MSCs (hMSCs) to graft versu...

    Authors: Joseph Delano Robles, Yin Ping Liu, Jiamin Cao, Zheng Xiang, Yin Cai, Michael Manio, Eva HC Tang and Godfrey Chi-Fung Chan
    Citation: Experimental Hematology & Oncology 2015 4:13
    Content type: Research Published on:

  24. Lactate levels within tumors are correlated with metastases, tumor recurrence, and radioresistance, thus apparently contributing to poor outcomes in patients with various cancers. We previously reported that h...

    Authors: Shiho Fujiwara, Naoko Wada, Yawara Kawano, Yutaka Okuno, Yoshitaka Kikukawa, Shinya Endo, Nao Nishimura, Nina Ueno, Hiroaki Mitsuya and Hiroyuki Hata
    Citation: Experimental Hematology & Oncology 2015 4:12
    Content type: Research Published on:

  25. Temsirolimus, a selective inhibitor of the mammalian target of rapamycin, has demonstrated clinical benefit versus investigator’s choice (INV) of therapy in patients with relapsed/refractory mantle cell lympho...

    Authors: Georg Hess, Bertrand Coiffier, Michael Crump, Christian Gisselbrecht, Fritz Offner, Jorge Romaguera, Lisa Kang and Pádraig J Moran
    Citation: Experimental Hematology & Oncology 2015 4:11
    Content type: Research Published on:

  26. The aim of this study was to elucidate the mechanisms responsible for the location of B-cell non-Hodgkin’s lymphoma (B-NHL) at different anatomical sites. We speculated that the malignant B cells in these diso...

    Authors: Stephen Middle, Sarah E Coupland, Azzam Taktak, Victoria Kidgell, Joseph R Slupsky, Andrew R Pettitt and Kathleen J Till
    Citation: Experimental Hematology & Oncology 2015 4:10
    Content type: Research Published on:

  27. Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocyte...

    Authors: Seong-Su Han, Van S Tompkins, Dong-Ju Son, Sangwoo Han, Hwakyung Yun, Natalie L Kamberos, Casey L Dehoedt, Chunyan Gu, Carol Holman, Guido Tricot, Fenghuang Zhan and Siegfried Janz
    Citation: Experimental Hematology & Oncology 2015 4:9
    Content type: Research Published on:

  28. A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and rituximab, which produced a complete remission. Eight months after the last dose of rituximab he ha...

    Authors: Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría, Juan M Sepúlveda and Juan F García
    Citation: Experimental Hematology & Oncology 2015 4:8
    Content type: Case report Published on:

  30. The role of platelets extends beyond hemostasis. The pivotal role of platelets in inflammation has shed new light on the natural history of conditions associated with acute or chronic inflammation. Beyond the ...

    Authors: Antoine Dewitte, Annabelle Tanga, Julien Villeneuve, Sébastien Lepreux, Alexandre Ouattara, Alexis Desmoulière, Christian Combe and Jean Ripoche
    Citation: Experimental Hematology & Oncology 2015 4:6
    Content type: Review Published on:

  32. Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of...

    Authors: Jesper Kofoed Damm, Sandra Gordon, Mats Ehinger, Mats Jerkeman, Urban Gullberg, Anne Hultquist and Kristina Drott
    Citation: Experimental Hematology & Oncology 2015 4:4
    Content type: Rapid communication Published on:

  33. Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castlem...

    Authors: Silvia Tedesco, Laura Postacchini, Lucia Manfredi, Gaia Goteri, Michele M Luchetti, Antonella Festa, Armando Gabrielli and Giovanni Pomponio
    Citation: Experimental Hematology & Oncology 2015 4:3
    Content type: Case report Published on:

  35. Because up to 30% of breast cancer cases may relapse, understanding the biology of recurrent breast cancer is imperative in preventing these poor outcomes. Thus, we present this unusual case of a BRCA2 carrier...

    Authors: Polly Niravath, Tanya Eble, Alejandro Contreras, Marilyn Li, Luis M Franco and Mothaffar Rimawi
    Citation: Experimental Hematology & Oncology 2015 4:1
    Content type: Case report Published on:

  36. The combination of rituximab and 2-CdA is an effective therapy for B-cell tumors. However, the molecular mechanisms and enzymatic pathways involved in the interaction between the two agents are not fully under...

    Authors: Ayad M Al-Katib, Amro Aboukameel, AbdulShukkur Ebrahim, Frances WJ Beck, Samuel E Tekyi-Mensah, Ali Raufi, Yasin Ahmed, Mary Mandziara and Zyad Kafri
    Citation: Experimental Hematology & Oncology 2014 3:31
    Content type: Research Published on:

  37. Tissue factor (TF) exposed on activated monocytes and macrophages is involved in thrombosis through activation of factor X and cytokine release, responsible for inflammation and thrombosis. We investigated the...

    Authors: Marc Laurent, Ulrich Joimel, Rémi Varin, Lionel Cazin, Caroline Gest, Veronique Le-Cam-Duchez, Jian Jin, Jielin Liu, Jean-Pierre Vannier, He Lu, Jeannette Soria, Hong Li and Claudine Soria
    Citation: Experimental Hematology & Oncology 2014 3:30
    Content type: Research Published on:

  38. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite the use of optimized first-line therapy, GBM is still associated with a poor prognosis and an effective second-...

    Authors: Katrin Schweneker, Christoph Clemm, Melanie Brügel, Michael Souvatzoglou, Mirjam Hermisson, Friederike Schmidt-Graf, Claus Zimmer, Christian Peschel and Philipp J Jost
    Citation: Experimental Hematology & Oncology 2014 3:29
    Content type: Case report Published on:

  39. T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive subtype of chronic lymphocytic leukemia. Usually it presents in older people with a median age of 61 years. T-PLL is characterized by elevated wh...

    Authors: Abdulsamad Wafa, Abdulmunim Aljapawe, Moneeb AK Othman, Thomas Liehr, Eyad Alhourani and Walid Al Achkar
    Citation: Experimental Hematology & Oncology 2014 3:28
    Content type: Case report Published on:

  41. We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselect...

    Authors: Teresa Moran, Enriqueta Felip, Vicki Keedy, Hossein Borghaei, Frances A Shepherd, Amelia Insa, Holly Brown, Timothy Fitzgerald, Sriram Sathyanarayanan, John F Reilly, David Mauro, Karl Hsu, Li Yan and David H Johnson
    Citation: Experimental Hematology & Oncology 2014 3:1
    Content type: Research Published on:

  42. Tobacco, alcohol and HPV infection are associated with increased risk of HNSCC. However, little is known about the underlying signaling events influencing risk. We aimed to investigate the relationship between...

    Authors: Mohammad R Islam, Ian R Ellis, Michaelina Macluskey, Lynda Cochrane and Sarah J Jones
    Citation: Experimental Hematology & Oncology 2014 3:25
    Content type: Research Published on:

  43. Cholesterol plays an important role in cancer development, drug resistance and chemoimmuno-sensitivity. Statins, cholesterol lowering drugs, can induce apoptosis, but also negatively interfere with CD-20 and r...

    Authors: Indira Benakanakere, Tyler Johnson, Richard Sleightholm, Virgilio Villeda, Monika Arya, Ravi Bobba, Carl Freter and Chunfa Huang
    Citation: Experimental Hematology & Oncology 2014 3:24
    Content type: Research Published on:

  44. Hormone-refractory breast cancer metastatic to bone is a clinically challenging disease associated with high morbidity, poor prognosis, and impaired quality of life owing to pain and skeletal-related events. I...

    Authors: Amol Takalkar, Scott Adams and Vivek Subbiah
    Citation: Experimental Hematology & Oncology 2014 3:23
    Content type: Short report Published on:

  45. Little is known about the epidemiology of MDS in minority populations. The IPSS and newly released IPSS-R are important clinical tools in prognostication of patients with MDS. Therefore, we conducted a retrosp...

    Authors: Ashwin Sridharan, Rishi Jain, Marcus A Bachhuber, Yiting Yu, KH Ramesh, Krishna Gundabolu, Ellen W Friedman and Amit K Verma
    Citation: Experimental Hematology & Oncology 2014 3:22
    Content type: Research Published on:

  46. Acquired hemophilia A (AHA) and acquired von Willebrand Syndrome (AVWS) are both rare bleeding disorders that can be associated with lymphoproliferative or autoimmune diseases. AHA is uniformly caused by inhib...

    Authors: Christina Dicke, Katharina Holstein, Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim, Carsten Bokemeyer, Christof Iking-Konert, Ulrich Budde and Florian Langer
    Citation: Experimental Hematology & Oncology 2014 3:21
    Content type: Case report Published on:

  47. Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, an...

    Authors: Elisa Rogowitz, Hani M Babiker, Mohammed Kanaan, Rebecca A Millius, Q Scott Ringenberg and Maria Bishop
    Citation: Experimental Hematology & Oncology 2014 3:20
    Content type: Case report Published on:

  48. Authors: B Douglas Smith, Charles L Beach, Dalia Mahmoud, Laura Weber and Henry J Henk
    Citation: Experimental Hematology & Oncology 2014 3:19
    Content type: Erratum Published on:

    The original article was published in Experimental Hematology & Oncology 2014 3:10

  49. Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) proliferation, rarely associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KITD816V is regarded as driver-mutation in SM...

    Authors: Markus Rechsteiner, Rouven Müller, Tanja Reineke, Jeroen Goede, Annette Bohnert, Qing Zhong, Markus G Manz, Holger Moch, Peter J Wild, Dieter R Zimmermann and Marianne Tinguely
    Citation: Experimental Hematology & Oncology 2014 3:18
    Content type: Rapid communication Published on:

  50. The miR-29 family have been demonstrated acting as vital tumor suppressor in multiple cancers as well as regulators in the adaptive immune system. Little is known about their role in leukemogenesis. The purpos...

    Authors: Ling Xu, Yan Xu, Zhenyi Jing, Xu Wang, Xianfeng Zha, Chengwu Zeng, Shaohua Chen, Lijian Yang, Gengxin Luo, Bo Li and Yangqiu Li
    Citation: Experimental Hematology & Oncology 2014 3:17
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 9.4
    5-year Journal Impact Factor: 8.3
    Source Normalized Impact per Paper (SNIP): 1.583
    SCImago Journal Rank (SJR): 2.384

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 696,150
    Altmetric mentions: 375

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us